Blog - End of Year Updates
Review of the AS/NZS standard for oral fluid drug testing
This has been under review throughout 2017, and a draft Standard was released for public comment.
There were over 200 comments submitted to Australian Standards regarding many of the proposed changes, causing he revision to be reconsidered and prepared for a second round of public comment.
It is likely that comments will be called in early 2018, delaying the eventual adoption date of the revised Standard.
Codeine to be prescription only
This change has been under discussion and review since 2015, and is due to be implemented on 1 February 2018. This is delayed from the previously planned introduction of June 2017.
The rationale for the change is in part due to the estimated rate codeine-related deaths. These have doubled of between 2000 and 2009, increasing from 3.5 to 8.7 per million. The number of deaths due to accidental overdose jumped 9 per cent each year during the same period, representing about half of fatalities.
There were significant concerns raised by the Pharmacy Guild of Australia, who now provide information on the upscheduling of codeine.
Rather than going over the details of medical cannabis I thought it would be better to provide links to information provided by a range of stakeholders in this area:
Therapeutic Goods Administration presentation regarding the changes to legislation and scheduling of cannabis and its products;
A freelance presentation (with links to other presentations relating to earlier updates) that may represent the views of cannabis users more generally; and
A lawyer’s viewpoint of the same information.
Future Blog Ideas?
Finally, if any readers have any ideas for topics to include in a blog, relating to drug and alcohol use generally or drug and alcohol testing more specifically, we would love to hear from you, and address your questions directly.Share